Daily Ards Research Analysis
Today's analysis identified a pharmacokinetic exposure-response study of imatinib in critically ill patients with COVID-19-related acute respiratory distress syndrome. Despite higher total imatinib exposure in the ICU setting, unbound exposure was similar and showed no association with key clinical outcomes, underscoring the importance of focusing on unbound drug concentrations for repurposed, highly protein-bound agents.
Summary
Today's analysis identified a pharmacokinetic exposure-response study of imatinib in critically ill patients with COVID-19-related acute respiratory distress syndrome. Despite higher total imatinib exposure in the ICU setting, unbound exposure was similar and showed no association with key clinical outcomes, underscoring the importance of focusing on unbound drug concentrations for repurposed, highly protein-bound agents.
Research Themes
- Drug repurposing in ARDS
- Pharmacokinetics in critical illness
- Exposure-response modeling for dosing optimization
Selected Articles
1. Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome.
In a post-hoc exposure-response analysis from two randomized trials (CounterCOVID, InventCOVID), critically ill C-ARDS patients exhibited higher total but similar unbound imatinib exposure. No exposure-response relationship was detected with WHO clinical score, P/F ratio, ICU stay, ventilator-free days, or mortality, suggesting dosing strategies should consider unbound concentrations in highly protein-bound drugs.
Impact: This study provides a rigorous negative exposure-response finding in ICU patients, informing the limits of imatinib repurposing for C-ARDS and emphasizing unbound drug levels in dosing decisions. It advances pharmacometric understanding in critical illness.
Clinical Implications: Standard imatinib dosing does not show an exposure-linked clinical benefit in critically ill C-ARDS, arguing against therapeutic drug monitoring aimed at higher total exposures. Dosing strategies, if pursued, should prioritize unbound concentrations and account for protein binding changes in critical illness.
Key Findings
- Critically ill C-ARDS patients had higher total imatinib exposure but similar unbound exposure compared with reference populations.
- No exposure-response association was found between imatinib (total, unbound, or plus metabolite) and WHO score, P/F ratio, ICU length of stay, ventilator-free days, or mortality.
- Critical illness and concomitant treatments significantly influenced imatinib exposure.
- Simulation-based PK modeling enabled individual parameter estimation for total, unbound, and metabolite-summed exposures.
Methodological Strengths
- Use of two randomized placebo-controlled trial datasets with invasive ventilation, enhancing internal validity.
- Population PK modeling with individual parameter estimation and mixed-effects analyses across multiple clinical endpoints.
Limitations
- Post-hoc design with modest sample size (n=53) limits causal inference and power.
- Heterogeneity in dosing routes (oral vs. intravenous) and duration may introduce confounding.
- Potential residual confounding from critical illness severity and concomitant medications.
Future Directions: Prospective, pre-specified exposure-response trials focusing on unbound concentrations and protein binding dynamics in ICU populations, with harmonized dosing routes and therapeutic drug monitoring frameworks.
INTRODUCTION: Imatinib, initially approved for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), was investigated in two randomized placebo-controlled trials for its potential effect on COVID-19-related ARDS (C-ARDS). A known relationship between imatinib concentrations and effectiveness exists in CML and GIST, but this is uncharacterized in critically ill C-ARDS patients, where standard dosing may not be suitable. AIMS: This study aims to explore the association between unbound imatinib, total imatinib, and total N-desmethyl-imatinib exposure with clinical outcomes in critically ill C-ARDS patients. METHODS: This post-hoc analysis included C-ARDS patients from the CounterCOVID and InventCOVID trials, all requiring invasive ventilation. In the CounterCOVID trial, patients received 800 mg imatinib on day 1, followed by 400 mg once daily for 9 days. In InventCOVID, the dose was 200 mg intravenously twice daily for 7 days or until ICU discharge. A pharmacokinetic (PK) model simulated the concentration-time profiles of total imatinib (T), unbound imatinib (U), and the sum of total imatinib plus its metabolite desmethyl-imatinib (PM). PK samples were used to estimate individual PK parameters, after which associations with clinical outcomes (WHO score, P/F ratio, ICU stay, ventilator-free days, and mortality) were tested using linear mixed models and regression analysis. RESULTS: Data from 53 patients revealed that critically ill patients reached higher total imatinib exposure but similar unbound imatinib exposure compared to others. Critical illness and concurrent treatments influenced imatinib exposure. No clear exposure-response relationship was found between imatinib exposure and clinical outcomes. CONCLUSION: Although critical illness was linked to higher imatinib exposure, no exposure-response relationship was found. Disease severity may have also impacted the drug's effectiveness, suggesting that ICU patients may require adjusted dosing. Future clinical studies of repurposed drugs should focus on exposure-response relationships to better understand optimal dosing in new patient populations, particularly for highly protein-bound drugs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04794088, registered 11 March 2021. European Clinical Trials Database (EudraCT number: 2020-005447-23).